Member Info for Jelenko

Malachi,
wrong. Parsortix isolates and harvests CTC's , It also shows CTDNA etc it's just that Angle have sensibly avoided targeting the mass screening market and instead focused on patients with symptoms and metastatic progression. far more important than mass screening

Don't agree with that Researcher. This is more about MM's habits than traders trying to be smart. Nobody ever really knows why prices oscillate but people just make up their own reasons when in fact there is likely no reason. My reason is it's Wednesday and it always drops on a Wednesday, or its 19th of the month and as we all know it has a mid to late mid month retrace. It actually doesn't really matter because in the case of AGL it's likely best to sit on your hands ond not try to be too clever trading. As we know 80% of retail traders lose money, fact.

From Mr. Market of course. But at what price?

It's already been a long haul for me !!

I am a fan of A.N, but the way AGL have worked recently I am thinking last week of May, work always expands to fill the time available to do it in. fact of life and business.

Over the years I have traded using Sp.Bet, CFD, etc. Did well in the 2007/8 crash etc but the thing to remember is that 80-90% of retail traders lose money, traders rarely talk about losers only trumpet winners. Unless you are a professional, there is a tendency to run loses hoping for a turn and take profits too early frightened of it evaporating. Charts do paint a picture of course but more useful in hindsight, yes support and resistance points are obvious on charts but unless trading makes no odds. Over the past 20 years I have found the best way to make good returns in the market is to identify a company or two at the most that will either move from loss making to profit or have growth plans that you can convert into real earnings. Calculate realistic share prices over a future time period and buy blow your future valuation, If the company moves over your future valuation too early sell and wait for pull back to buy back in. Trading too often increases the risk of making an error and trades feel the need to be busy trading so often overtrade and wipe out previous gains.

Sight tight in AGL until it hits you own target , my target here is £15 FWIW. GLA

Phantom I think we all know that revenue is for vanity and profit is for sanity and also that EXAS are not making profit BUT the
Americans don't seem to care about profit so I think it is fair to compare on a revenue basis. Normally I would work PE's on profit also but in this case you have to have a different approach.

can't see the reason for a large pharma to buy AGL, as A.N. said in the interview they outsource their drug trial analysis anyway.
If anyone it will be a large player already in the Liquid biopsy space. and that could spark a biding war.

Phantom, EXAS, a lab based company in the U.S that AGL have used as a comparison are on a sales multiple of 25 times!
Still not making a profit, mkt cap £22b!!!

I thought his comment about current lab capacity interesting, 25,000 tests per year at each lab. so 50,000 tests and a price of between $1000 and $2000 per test. So at that we have a lab sales revenue capacity of between $50-$100m per year.
That's now not pie in the sky stuff. I think 99p a tad low.

I think some people haven't fully understood what AGL can and can't do without FDA approval. Simply, in their labs now they can do what they want for research purposes e.g drug trials etc. When accredited ( in a few months) they can process clinical samples, so from real patients etc. That's because the whole lab is accredited.
When selling the device and cassettes into the clinical market e.g. hospitals for third party use, they need FDA for the device and the proposed application use.

Yes, I noticed the flag. Normally though the eventual rise is the same as the flagpole length so over 40p in this case which takes us north of 120p.

I think we all know that after many tears of work, hoops to jump through etc. The the B.O.D would not recommend a £4 offer, nor £8 in fact. So we need patience here, just a bit more than we have already shown. FDA approval will make this the gold standard and with that a substantial de risking and subsequent sp. upgrade. We should not confuse a rerated sp. post clinical lab contracts and FDA approval with a T.O. price. Different all together.

Quite reasonable by the end of April I feel.

I think Money inflows will do it myself, first new ISA month etc. Looking for a sustained boost around 16th to end of Month.
I have 106p in my mind.

I'm fairly confident that we will break £1 this month.

55-65 Dream on.

Nah, looking at over100p in April any retrace will be bought heavily until FDA then BOOM!!!

Anyone shorting this needs a doctors appointment.

Hi Researcher,
I have in the past spoken to A.N about the derisory broker target of 150p. He responded by saying that the 150p target was for now not after FDA! Also my logic for the April figure is driven by the fact that during the past two years the sp. has gone up by over 30% in April. This I believe is new ISA money inflows and this year people have every reason if not more to pile in ASAP.